Research Corner: Health Disparities Focus Group
By Dorothy Reed, Chair, Community Cancer Action Board
Palliative Medicine and Supportive Care Program
*/
/*-->*/
/*-->*/
CAR T-Cell Therapy Available at Rutgers Cancer Institute and Robert Wood Johnson University Hospital
Between 60 to 70 percent of patients with aggressive non-Hodgkin lymphoma are cured with initial chemotherapy and a significant percentage of patients who relapse are cured with a stem cell transplant using the patient’s own cells. However, in patients whose disease becomes resistant to chemotherapy, the average survival is only six months. Until recently, those with B-cell lymphomas that did not respond to standard therapies had limited treatment options.
LGBTQ Health
/*-->*/
/*-->*/
Educational Program Offerings
- Prevention and Early Detection of HPV-Related Cancers for the LGBTQ Community
